The JAK2V617F mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden

Abstract Alleviating symptom burden in patients with myeloproliferative neoplasms (MPNs) is imperative to achieving optimal management. Research remains to elucidate the relationship between the JAK2V617F (Janus kinase 2) mutation present in many MPN patients, and the symptomatology they experience....

Cijeli opis

Bibliografski detalji

Glavni autori:	Lai Yee Orbell, Nouf Abutheraa, Andrew S Duncombe, Mary Frances McMullin, Ruben Mesa, Charlene M McShane, Glen James, Lesley A Anderson
Format:	Artigo
Jezik:	Inglês
Izdano:	Wiley 2023-11-01
Serija:	eJHaem
Teme:	essential thrombocythaemia Janus kinase 2 management myeloproliferative neoplasm polycythaemia vera primary myelofibrosis
Online pristup:	https://doi.org/10.1002/jha2.805
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!